OPG as a risk factor for the primary end point ( cardiovascular death , nonfatal myocardial infarction , nonfatal stroke ; n = 318 ) , all-cause mortality ( n = 329 ) , and all-cause mortality/hospitalization for worsening of heart failure ( WHF ; n = 475 ) was investigated in 1464 patients ( 60 years , New York Heart Association class II to IV , ischemic systolic HF , optimal pharmacological therapy ) in the Controlled Rosuvastatin Multinational Trial in HF ( CORONA ) population , randomly assigned to 10 mg rosuvastatin or placebo .
